Drug repositioning from bench to bedside: tumour remission by the antihelmintic drug mebendazole in refractory metastatic colon cancer (2014)

Other · Nygren P, Larsson R · March 2014

Nygren P et al., 2014-03: Case report of a 74-year-old man with refractory metastatic sigmoid colon cancer who had near-complete remission of lung and lymph-node metastases and good partial remission in the liver after six weeks of mebendazole. Liver enzymes rose five- to seven-fold and the drug was briefly stopped, then resumed at half dose.

the patient, after informed consent, started mebendazole at the standard antihelmintic dose of 100 mg twice daily, to be continued for six weeks

2

Nygren P et al., 2014-03: Case report of a 74-year-old man with refractory metastatic sigmoid colon cancer who had near-complete remission of lung and lymph-node metastases and good partial remission in the liver after six weeks of mebendazole. Liver enzymes rose five- to seven-fold and the drug was briefly stopped, then resumed at half dose. Study type: case report. N=1. Country: Sweden (Uppsala University Hospital). Dose: mebendazole 100 mg orally twice daily for six weeks, then half dose after transient transaminase elevation. Funder: not stated. Conflicts: not stated in the available text. Maker: the paper names Vermox as the tradename. Comparator: none; the patient had progressed on capecitabine/oxaliplatin/bevacizumab and capecitabine/irinotecan. Outcome assessed by CT: near-complete remission in lungs and lymph nodes, good partial remission in liver. The publisher page carries no abstract text; the full text is a third-party PDF of the Acta Oncologica letter, and the quote is on page 2 of that PDF.